Humacyte, Inc.Humacyte, Inc.Humacyte, Inc.

Humacyte, Inc.

No trades
See on Supercharts
Market capitalization
‪440.61 M‬USD
−1.07USD
‪−110.78 M‬USD
‪89.92 M‬
Beta (1Y)
0.44

About Humacyte, Inc.

CEO
Laura E. Niklason
Headquarters
Durham
Employees (FY)
183
Founded
2004
ISIN
US44486Q1031
FIGI
BBG00XPPT7S7
Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of HUMA is 3.70 USD — it has increased by 3.06% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Humacyte, Inc. stocks are traded under the ticker HUMA.
Humacyte, Inc. is going to release the next earnings report on May 10, 2024. Keep track of upcoming events with our Earnings Calendar.
HUMA stock is 15.77% volatile and has beta coefficient of 0.44. Check out the list of the most volatile stocks — is Humacyte, Inc. there?
One year price forecast for Humacyte, Inc. has a max estimate of 15.00 USD and a min estimate of 4.00 USD.
HUMA earnings for the last quarter are −0.25 USD per share, whereas the estimation was −0.25 USD resulting in a 1.63% surprise. The estimated earnings for the next quarter are −0.24 USD per share. See more details about Humacyte, Inc. earnings.
Humacyte, Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of ‪66.67 K‬ USD. In the next quarter revenue is expected to reach ‪50.00 K‬ USD.
Yes, you can track Humacyte, Inc. financials in yearly and quarterly reports right on TradingView.
HUMA stock has risen by 22.11% compared to the previous week, the month change is a 3.64% rise, over the last year Humacyte, Inc. has showed a 10.28% increase.
HUMA net income for the last quarter is ‪−25.11 M‬ USD, while the quarter before that showed ‪−26.00 M‬ USD of net income which accounts for 3.42% change. Track more Humacyte, Inc. financial stats to get the full picture.
Today Humacyte, Inc. has the market capitalization of ‪440.61 M‬, it has increased by 4.38% over the last week.
No, HUMA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, HUMA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Humacyte, Inc. stock right from TradingView charts — choose your broker and connect to your account.
HUMA reached its all-time high on Sep 1, 2021 with the price of 17.45 USD, and its all-time low was 1.96 USD and was reached on Dec 30, 2022.
See other stocks reaching their highest and lowest prices.
As of Apr 21, 2024, the company has 183.00 employees. See our rating of the largest employees — is Humacyte, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Humacyte, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Humacyte, Inc. stock shows the buy signal. See more of Humacyte, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Humacyte, Inc. future price: according to them, HUMA price has a max estimate of 15.00 USD and a min estimate of 4.00 USD. Read a more detailed Humacyte, Inc. forecast: see what analysts think of Humacyte, Inc. and suggest that you do with its stocks.